TissueGene Licensee, Kolon Life Science, Partners with Mitsubishi Tanabe Pharma to Develop and Commercialize Invossa™, the World's First Cell-Mediated Gene Therapy for Degenerative Osteoarthritis Nov 1, 2016
Regenerative Medicine Company, TissueGene, adds Dr. Gurdyal Kalsi as Chief Medical Officer Feb 16, 2016
TissueGene, Inc. Announces FDA Acceptance Of Invossa™ As Proprietary Name For TissueGene-C Jun 24, 2015
TissueGene Announces Presentation and Webcast at the Jefferies 2015 Healthcare Conference May 28, 2015
TissueGene, Inc. Announces Special Protocol Assessment (SPA) Agreement with the Food and Drug Administration (FDA) for its Phase 3 Clinical Trial of Invossa™ for Patients Suffering from Osteoarthritis of the Knee May 15, 2015
TissueGene, Inc. Presents Phase 2 Data for Its Novel Cell Therapy for the Treatment of Osteoarthritis of the Knee May 11, 2015
TissueGene Receives Recommendations from FDA on Pathway to Phase 3 Trial of TG-C for Treatment of Osteoarthritis of the Knee Nov 17, 2014
TissueGene Completes Enrollment in U.S. Phase II Study of TG-C in Patients with Knee Osteoarthritis Nov 14, 2012
TissueGene Initiates Patient Enrollment for a Phase II Study of TG-C for Osteoarthritis of the Knee May 19, 2011
